Release of Research Publication using Tribody™ Technology onto Cancer Immunotherapy from Chiome Bioscience (JP) in collaboration with CEINGE (IT)

Tribodies combining blockers for PD-1, PD-L1 and LAG-3 showed enhanced activity on activating lymphocytes as compared to a mix of the parental mAbs, with lower toxicity on normal tissue.